SARS-CoV-2 mRNA Codon Optimization for Broad Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for codon optimization in mRNA vaccines for COVID-19 are limited by computational and therapeutic drawbacks, and there is a need for improved sequences that enhance expression and provide broad neutralization against SARS-COV-2 variants.
Innovation Solution
Development of optimized nucleotide sequences for SARS-COV-2 spike proteins, including modifications such as removing the furin cleavage site and mutating residues 986 and 987 to proline, which are designed to increase expression and induce a broadly neutralizing antibody response against various SARS-COV-2 variants, using lipid nanoparticles for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional codon optimization methods are used (replacing every codon with the most frequent codon for each amino acid), then computational simplicity is achieved, but the resulting sequences may have reduced therapeutic efficacy and expression levels
Solution Approach 1:
The patent changes the parameters of codon optimization by moving beyond simple frequency-based selection to incorporate multiple factors including RNA secondary structure prediction, codon pair bias, and contextual sequence features. This multi-parameter approach resolves the contradiction by achieving both computational tractability and improved therapeutic efficacy through sophisticated algorithms that consider RNA stability, translation efficiency, and protein expression levels simultaneously.
Solution Approach 2:
The optimized nucleotide sequences combine multiple optimization strategies into a composite approach, integrating codon usage frequency data, RNA structure predictions, and codon pair optimization metrics. This composite methodology resolves the technical contradiction by synthesizing various computational techniques to achieve superior therapeutic efficacy while maintaining computational feasibility.
2Stability of the object's composition
If the furin cleavage site is removed and residues 986-987 are mutated to proline, then protein stability and prefusion conformation are improved, but the sequence diverges further from the wild-type virus
Solution Approach 1:
The patent applies preliminary anti-action by pre-stabilizing the spike protein in its prefusion conformation through the P986G and P987G mutations and furin site removal, preventing the protein from transitioning to the postfusion state. This resolves the contradiction by locking the antigen in a conformation that elicits broadly neutralizing antibodies while maintaining immunogenicity across SARS-CoV-2 variants.
Solution Approach 2:
The patent changes the structural parameters of the spike protein by introducing specific point mutations (P986G, P987G) and deleting the furin cleavage site, which alters the protein's conformational dynamics. These parameter changes stabilize the prefusion state while preserving the antigenic determinants necessary for broad neutralization across variants.
3Productivity
If codon optimization is performed to maximize expression, then protein yield is increased, but the nucleotide sequence may acquire unwanted secondary structures or regulatory elements
Solution Approach 1:
The patent implements feedback mechanisms by iteratively predicting RNA secondary structures and scanning for regulatory elements during the codon optimization process. The algorithm adjusts codon selections based on feedback from structure predictions, removing sequences that form stable hairpins or contain unwanted regulatory motifs while maintaining high expression potential. This resolves the contradiction by dynamically balancing expression optimization with sequence complexity constraints.
Solution Approach 2:
The patent performs preliminary screening of codon sequences for unwanted secondary structures and regulatory elements before finalizing the optimized sequence. By anticipating and preventing structural problems in advance, the method achieves high protein expression without introducing nucleotide sequence complexity that could interfere with vaccine performance.
Data Source
AI summary
The present invention relates to optimized nucleotide sequence encoding SARS-COV-2 antigens. These sequences are particularly suitable for use in vaccine compositions for the treatment or prevention of infections caused by a β-coronaviruses, including COVID-19 infections, in a human or animal subject in need of such treatment.